Ligand Pharmaceuticals, Inc.
LGNDZ
Get informed when a big investor buys or sells
+ FollowMarket Cap$6.05B
Close$
Share Statistics
| Market cap | $6.05 Billion |
|---|---|
| Enterprise Value | $5.82 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $6.44 |
| Beta | 0.98 |
| Outstanding Shares | 20,063,000 |
Return
| Return on Equity | 19.07% |
|---|---|
| Return on Assets | 8.44% |
| Return on Invested Capital | 10.27% |
Valuation & Multiples
| P/E Ratio | 0 |
|---|---|
| PEG | 0 |
| Price to Sales | 0.0 |
| Price to Book Ratio | 0.0 |
| Enterprise Value to Revenue | 20.02 |
| Enterprise Value to EBIT | 26.47 |
| Enterprise Value to Net Income | 31 |
| Total Debt to Enterprise | 0.19 |
| Debt to Equity | 1.16 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 6, 2026
EPS Estimate
$2.01
Average shareholder expectationRevenue Estimate
$61.30 M
Average shareholder expectationNext Earnings Call
Expected Date
November 5, 2026
EPS Estimate
$2.31
Average shareholder expectationRevenue Estimate
$77.95 M
Average shareholder expectationInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About Ligand Pharmaceuticals, Inc.
47 employees
CEO: John Higgins Ligand Pharmaceuticals, Inc. functions as a biopharmaceutical firm, primarily focusing on developing and acquiring innovative technologies that empower other pharmaceutical companies in their drug discovery and development processes. Its...